Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

Citi raised its CRISPR Therapeutics price target from $82 to $88 per share, about 60% above the stock's cited current price, with the outlook tied to Casgevy revenue growth and pipeline progress. Casgevy generated $76 million in total revenue over three months, though Vertex processes payments and takes a share; treatment costs $2.2 million per patient and can take up to a year to complete. CRISPR expects a Phase 1 update on CTX310 before year-end, while analysts project revenue rising from $40.8 million this year to $156.6 million next year.

Analysis

The key underwriting distinction is patient demand versus monetizable revenue. Casgevy’s per-patient price and reported gross sales are poor proxies for CRSP’s recognized share: treatment-center capacity, authorization-to-infusion delays, collections, and the undisclosed collaboration split determine when and how much reaches CRSP. Track treated patients and CRSP’s reported collaboration revenue, not headline sales; a launch that is clinically successful but operationally slow can still disappoint near-term estimates. VRTX participates in the commercial upside, but the economics are not a clean hedge for CRSP’s pipeline risk.

CTX310 is a higher-variance catalyst than the article’s market-size framing implies. A Phase 1 signal must establish durable lipid reduction and an acceptable safety profile for an irreversible edit; chronic, titratable therapies from established lipid-lowering competitors remain the comparison set. Zugo-cel’s potential manufacturing advantage is likewise conditional: allogeneic scale does not ensure persistence, safety, or repeatable efficacy. These programs support optionality, not yet a basis for capitalizing CRSP like a mature platform.

The contrarian risk is that investors treat one-off gross Casgevy sales and a broad addressable market as evidence of a near-term earnings inflection. Conversely, if CRSP’s reported share and patient throughput accelerate, the market may underprice the operating leverage. The article’s catalyst dates and forecast periods are ambiguous relative to today; verify whether the cited CTX310 update has already occurred before trading it.

Key Decisions for Investors

• Do not underwrite CRSP to an analyst price target from this article. Before adding exposure, verify the latest CRSP-reported Casgevy revenue, treatment starts/completions, reimbursement conversion, and collaboration economics; falsification is persistently weak recognized revenue despite rising gross sales.
• Treat CTX310 as an event-driven, high-risk catalyst, not a near-term earnings driver. Confirm the readout is still pending and its date; only consider a small, defined-risk call spread after confirmation, with the premium at risk limited to an amount tolerable for a Phase 1 safety/efficacy disappointment.
• Keep VRTX as the lower-pipeline-risk way to participate in Casgevy commercialization, but do not assume it offsets CRSP one-for-one. Reassess the relative view if CRSP discloses materially stronger-than-expected revenue conversion or if VRTX’s collaboration economics differ from expectations.
• Watch for evidence beyond market-size claims on CTX310 and zugo-cel: lipid reduction durability and adverse events for CTX310; response durability, safety, and manufacturing consistency for zugo-cel. Weakness on these measures would undercut the platform-optionality premium.